Phase I trial of BHV 0223, a reformulated glutamate modulating agent, as a potential therapy for treatment-resistant mood and general anxiety disorders

Trial Profile

Phase I trial of BHV 0223, a reformulated glutamate modulating agent, as a potential therapy for treatment-resistant mood and general anxiety disorders

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2016

At a glance

  • Drugs Riluzole (Primary)
  • Indications Generalised anxiety disorder; Mood disorders
  • Focus First in man; Pharmacokinetics
  • Most Recent Events

    • 05 Jul 2016 According to Biohaven Pharmaceuticals media release, as of August 2015, the FDA cleared the Company's IND for BHV-0223.
    • 24 Feb 2016 Results published in a Portage Biotech media release.
    • 24 Feb 2016 Results were published in a Biohaven Pharmaceutical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top